Diseases [C] » Skin and Connective Tissue Diseases [C17] » Connective Tissue Diseases » Scleroderma, Systemic » Scleroderma, Diffuse
Diseases [C] » Skin and Connective Tissue Diseases [C17] » Skin Diseases » Scleroderma, Systemic » Scleroderma, Diffuse
Description
A rapid onset form of SYSTEMIC SCLERODERMA with progressive widespread SKIN thickening over the arms, the legs and the trunk, resulting in stiffness and disability. MeSH
Hierarchy View
Approved Indicated Drugs (1)
Phase 3 Indicated Drugs (2)
Phase 2 Indicated Drugs (18)
Phase 1 Indicated Drugs (4)
Other Experimental Indicated Drugs (2)
Organization Involved with Phase 4 Indications (20)
Organization Involved with Phase 3 Indications (53)
Institute of Post Graduate Medical Education & Research
Japan Agency for Medical Research and Development
Medical University of South Carolina
National Center for Research Resources (NCRR)
National Institute of Allergy and Infectious Diseases (NIAID)
Organization Involved with Phase 2 Indications (82)
Hellenic Institute for the Study of Sepsis
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Rainier Clinical Research Center
Rudolph Rupert Scleroderma Program
Salford Royal Foundation NHS Trust
Scleroderma Research Consultants LLC
South-Eastern Norway Regional Health Authority
Organization Involved with Phase 1 Indications (18)
Organization Involved with Other Experimental Indications (11)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
